OncoPharm
John Bossaer
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Episodes
Mentioned books
Jul 11, 2018 • 17min
Paclitaxel
We discuss paclitaxel, from its discovery to its uses to toxicity and their management as part of our Landmarks in #OncoPharm series. And if you really, really love this drug - you'll learn where to may homage at a historical marker in....
Jul 4, 2018 • 7min
Happy Fourth!
Our shortest Pod yet! Chemotherapy explosions and photosensitizing antineoplastics are discussed.
Jun 28, 2018 • 18min
Encorafenib & Binimetinib
The newly FDA-approved BRAF & MEK inhibitors are discussed, along with their possible clinical relevance and some notable differences compared to previously available BRAF & MEK inhibitors.
Jun 21, 2018 • 18min
The Immunotherapy Two Step
Immunotherapy takes two steps forward (new FDA approvals)....and two steps backwards. These updates in #oncopharm are discussed before ending (11:45) with discussions of venetoclax's expanded approval in CLL, the bevacizumab approval almost 7 years in the making, and late-breaking information on preventing cisplatin ototoxicity.
Jun 13, 2018 • 16min
Ondansetron Origins
The Landmarks in Oncology Pharmacy series returns with a review of 2 ondansetron studies from 1990, published simultaneously in NEJM.
Jun 7, 2018 • 24min
Less is More & More
Recapping (some) of the top stories from ASCO18 starting with breast cancer (TAILOR-Rx, PERSEPHONE, SANDPIPER, S0927); then NSCLC (11:35) with Keynote-42 & LOXO-292; then mylemoa (16:50) with a CAR-T update and a new dosing of carfilzomib; before ending (20:30) with CARMENA and PRODIGY-24's new mFOLFIRINOX data for adjuvant pancreatic cancer. Whew!
May 31, 2018 • 16min
ASCO18 & Under the Radar Abstracts
Previewing this week's ASCO annual meeting and the Plenary Sessions (briefly) and selected abstracts highlighting oncology pharmacy practice.
May 25, 2018 • 17min
Avatrombopag
Avatrombopag's FDA-approval prompts discussion of both the indication and drug itself. Finally, the publication of the SELECT-D study allows us to dig deeper into the data of a DOAC vs. LMWH in cancer-associated VTE.
May 19, 2018 • 13min
PERSEPHONE: Bonus Pod
The release of ASCO's 2018 annual abstracts resulted in widespread media coverage of PERSEPHONE, the largest trial yet investigating 6 vs. 12 months of adjuvant trastuzumab in breast cancer. We get into the history of adjuvant trastuzumab studies and what to watch for going forward.
May 18, 2018 • 12min
Cytarabine
Cytarabine, the 'c' chemotherapy from the sea, is discussed.
